ATE419855T1 - Therapie für hormonersatz und depression enthaltend dienogest - Google Patents

Therapie für hormonersatz und depression enthaltend dienogest

Info

Publication number
ATE419855T1
ATE419855T1 AT04744181T AT04744181T ATE419855T1 AT E419855 T1 ATE419855 T1 AT E419855T1 AT 04744181 T AT04744181 T AT 04744181T AT 04744181 T AT04744181 T AT 04744181T AT E419855 T1 ATE419855 T1 AT E419855T1
Authority
AT
Austria
Prior art keywords
therapy
hormone replacement
depression containing
dienogest
containing dienogest
Prior art date
Application number
AT04744181T
Other languages
English (en)
Inventor
Ina Rudolph
Thomas Graser
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Application granted granted Critical
Publication of ATE419855T1 publication Critical patent/ATE419855T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/10Drugs for disorders of the urinary system of the bladder
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18Feminine contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/14Drugs for dermatological disorders for baldness or alopecia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Surface Treatment Of Glass Fibres Or Filaments (AREA)
  • Lubricants (AREA)
  • Injection Moulding Of Plastics Or The Like (AREA)
AT04744181T 2003-06-25 2004-06-25 Therapie für hormonersatz und depression enthaltend dienogest ATE419855T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48215403P 2003-06-25 2003-06-25
US48843903P 2003-07-21 2003-07-21
PCT/IB2004/002535 WO2004112797A1 (en) 2003-06-25 2004-06-25 Hormone replacement- and depression therapy comprising dienogest

Publications (1)

Publication Number Publication Date
ATE419855T1 true ATE419855T1 (de) 2009-01-15

Family

ID=33544504

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04744181T ATE419855T1 (de) 2003-06-25 2004-06-25 Therapie für hormonersatz und depression enthaltend dienogest

Country Status (11)

Country Link
US (2) US20050032758A1 (de)
EP (1) EP1635843B1 (de)
JP (1) JP2007528358A (de)
AT (1) ATE419855T1 (de)
DE (1) DE602004018921D1 (de)
DK (1) DK1635843T3 (de)
ES (1) ES2320662T3 (de)
PL (1) PL1635843T3 (de)
PT (1) PT1635843E (de)
SI (1) SI1635843T1 (de)
WO (1) WO2004112797A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004019743B4 (de) 2004-04-20 2008-11-27 Bayer Schering Pharma Aktiengesellschaft Mehrphasenpräparat zur Kontrazeption auf der Basis eines natürlichen Estrogens
CA2566811A1 (en) * 2004-05-26 2005-12-15 Wyeth Compositions and methods for treatment of premenstrual dysphoric disorder
EP1774970A1 (de) * 2005-10-13 2007-04-18 Bayer Schering Pharma AG Verfahren zur Herstellung eines einphasigen pharmazeutischen Präparates zur Therapie der dysfunktionellen uterinen Blutung, enthaltend Ethinylestradiol und Dienogest
US8153616B2 (en) 2005-10-17 2012-04-10 Bayer Pharma Aktiengesellschaft Combination preparation for oral contraception and oral therapy of dysfunctional uterine bleeding containing estradiol valerate and dienogest and method of using same
EP1930010A1 (de) 2006-10-20 2008-06-11 Bayer Schering Pharma Aktiengesellschaft Verwendung von Estradiolvalerat oder 17ß-Estradiol in Kombination mit Dienogest zur oralen Therapie für den Erhalt und/oder die Steigerung der weiblichen Libido
US20100155594A1 (en) * 2008-12-23 2010-06-24 Goldman Mildred M Mass spectrometry assay for estrogenic compounds
BE1027858B1 (fr) * 2019-12-13 2021-07-14 Georges Debled Composition pharmaceutique pour la contraception chez la femme

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US165209A (en) * 1875-07-06 Improvement in automatic shut-off attachments for water-closets
US198671A (en) * 1877-12-25 Improvement in apparatus for recovering alkali from waste solutions
DE19525017A1 (de) * 1995-06-28 1997-01-02 Schering Ag Pharmazeutisches Kombinatonspräparat, Kit und Methode zur hormonalen Kontrazeption
JP2000515890A (ja) * 1996-07-26 2000-11-28 アメリカン・ホーム・プロダクツ・コーポレイション プロゲスチンとエストロゲンとの混合剤からなる一相性避妊法およびキット
US6306914B1 (en) * 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
CA2267743C (en) * 1999-03-30 2011-07-26 Robert F. Casper Low dose estrogen interrupted hormone replacement therapy
WO2003041718A1 (en) * 2001-11-15 2003-05-22 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
WO2003082299A1 (en) * 2002-04-03 2003-10-09 Jencap Research Ltd. Improved hormone replacement therapy

Also Published As

Publication number Publication date
PL1635843T3 (pl) 2009-06-30
WO2004112797A1 (en) 2004-12-29
DK1635843T3 (da) 2009-05-04
DE602004018921D1 (de) 2009-02-26
EP1635843B1 (de) 2009-01-07
US20120225853A1 (en) 2012-09-06
EP1635843A1 (de) 2006-03-22
PT1635843E (pt) 2009-04-07
ES2320662T3 (es) 2009-05-27
SI1635843T1 (sl) 2009-06-30
US20050032758A1 (en) 2005-02-10
JP2007528358A (ja) 2007-10-11

Similar Documents

Publication Publication Date Title
AR057060A1 (es) Composiciones de tanaproget que contienen etinil estradiol
HUP0301813A2 (hu) Nem-orális androgén szteroidok
WO2005077968A8 (en) 17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
BR0316203A (pt) Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
PL2131847T3 (pl) Lek zawierający przynajmniej jeden gestagen
MY137766A (en) Exemestane as chemopreventing agent
IL169583A0 (en) Composition comprising a combination of an aromatase inhibitor, a progestin and an oestrogen and its use for the treatment of endometriosis
AR040130A1 (es) Esteres de etonogestrel, su uso como anticopceptivo y para el tratamiento de desordenes ginecologicos
ATE382355T1 (de) Zusammensetzung, enthaltend ein androgenes 11-b- halogensteroid und ein gestagen sowie m nnliches kontrazeptivum auf basis dieser zusammensetzung
ATE419855T1 (de) Therapie für hormonersatz und depression enthaltend dienogest
SI1526856T1 (sl) Farmacevtski sestavek, ki obsega estetrolne derivate za uporabo pri zdravljenju raka
RS90504A (en) C-17 spirolactonization and 6,7 oxidation of steroids
CY1110173T1 (el) Χρηση της (11 beta, 17beta)-11-(1,3-benzodioxol-5-yl)-17-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one στη θεραπεια μειζωνος καταθλιπτικης διαταραχης
BR0214643A (pt) Aplicação de um antagonista h1, e um esteróide seguro para tratar rinite
DE602004014020D1 (de) Prävention und behandlung von hypertonen herzerkrankungen mit den selektiven östrogenen 8beta-vinyl-estra-1,3,5(10)-trien-3,17beta-diol und 17beta-fluor-9alpha-vinyl-estra-1,3,5(10)-trien-3,16alpha-diol
MXPA05010871A (es) Metodos para administrar estrogenos y progestinas.
MX2009000950A (es) Uso del antagonista del receptor de glucocorticoide para el tratamiento de padecimientos infecciosos.
AU2003285485A1 (en) 5 ANDROSTEN-3Beta-OL STEROID INTERMEDIATES AND PROCESSES FOR THEIR PREPARATION
BR9906862A (pt) Uso de uma quantidade eficaz de um agente desubstituição hormonal para o tratamento demenopausa humana e de endometriose
CY1110463T1 (el) Θεραπεια ορμονικης αντικαταστασης και καταθλιψης που περιλαμβανει διενογεστη
SI1589976T1 (sl) Uporaba kombinacije aromataznega inhibitorja, progestina in estrogena za zdravljenje endometrioze

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1635843

Country of ref document: EP